The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

An example blended oil composition includes a combination of Cannabidiol (CBD) oil extracted from Cannabis sativa, curcumin oil including one or more curcuminoids from turmeric rhizomes, and ginsenoside oil including one or more ginsenosides from at least one of Panax ginseng and P. quinquefolius. The Cannabis sativa comprises at least one of C. sativa, C. indica, and C. ruderalis. An example method of producing CBD oil is also disclosed.

Disclosed embodiments concern a composition and/or combination, and a method of administering the same as a feed, or to supplement the feed of, aquatic animals, particularly for aquaculture. Disclosed composition and/or combination embodiments may comprise glucan, silica, mineral clay, mannans, yucca, quillaja, a probiotic, and/or an adhesive agent. The adhesive agent may be selected particularly to facilitate administration to aquatic species. In certain embodiments the adhesive agent comprises an oil, such as soy oil, or a syrup, such as molasses, or combinations thereof. In some embodiments the composition and/or combination may further comprise polyphenol, an antimicrobial, and/or a vaccine. Also disclosed is a method for promoting growth and/or immune function in aquatic animals.

An organic acid salt of nicotinamide riboside (NR) is provided, where an organic acid is selected from the group consisting of malic acid, citric acid, royal jelly acid, and the like, and a molar ratio of the NR to the organic acid is 1:2 or 1:1. A compound composition of an organic acid salt of NR and a carrier is further provided, where the carrier is selected from the group consisting of niacin, glutamic acid, royal jelly acid, nervonic acid, microcrystalline cellulose (MCC), and apple cider vinegar powder. The present disclosure adopts an organic acid with strong acidity, and such an organic acid can form an intimate ion pair with NR and show some hydrophobicity, which improves the stability of NR. The carrier can prevent moisture penetration and improve the water resistance of the organic acid salt.

Disclosed herein are compositions and methods for cannabinoid delivery. The composition may include a suppository having one or more cannabinoids. The cannabinoids may include tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Disclosed herein are methods for delivering the cannabinoids or suppository rectally, vaginally, or intravenously. The cannabinoids and delivery method may treat a disease without inducing psychoactive effects.

Disclosed are various embodiments of lipid multiparticulate compositions comprising at least one active agent, a low flow point excipient, and a high flow point excipient.

A liquid capsule of cannabis, ginseng, and turmeric rhizome oil blend consisting essentially of an oil blend of cannabis oil, turmeric rhizome oil, and ginseng oil in a liquid capsule. There is less than 4 ppm of tetrahydrocannabinol (THC) in the oil blend.

Compositions and methods for providing one or more platelet-derived hemostatic agents to a treatment site are provided. Compositions and methods may be directed to bandages, carrier materials, and closure devices. Compositions and methods may be directed to treatment of neoplasias, including cancers. The platelet-derived hemostatic agents may include chemotherapeutic agents.

A mesoporous sponge spicule, a mesoporous material is synthesized on a surface of a sponge spicule to define the mesoporous sponge spicule.

A kit for an inhaled chemotherapy includes a series of single hermetically packaged therapeutic doses of a dry powder for inhalation. The dry powder includes at least one anti-neoplastic agent chosen from the group that includes platinum drugs with a lipid matrix and a PEGylated excipient and a series of disposable dry powder inhaler devices. The use and a method of treatment of cancer lungs with said kit is also described.